Wolfe Research analyst Mike Polark downgraded ResMed (NYSE: RMD) from Peerperform to Underperform with a price target of $180.00.The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE